Abiraterona en cáncer de próstata hormono-sensible metastásico

19 / 32

AE, %
ADT + AAP
(n = 597)
ADT + placebos
(n = 602)
Grade 3 Grade 4 Grade 3 Grade 4
Hypertension 20 0 10 0.2
Hypokalaemia 10 0.8 1 0.2
ALT increase 5 0.3 1 0
AST increase 4 0.2 1 0
Hyperglycaemia 4 0.2 3 0
Bone pain 3 0 3 0
Cardiac events 3 0.8 1 0
Anaemia 2 0.5 4 0.2
Back pain 2 0 3 0
Fatigue 2 0 2 0
Spinal cord
compression 2 0 1 0.5
Safety: CHAARTED and LATITUDE
1. Sweeney C, et al. N Engl J Med. 2015;373:737-46.
AE Grade 3 Grade 4 Grade 5
Patients, n (%)
Allergic reaction 7 (1.8) 1 (0.3) 0
Fatigue 16 (4.1) 0 0
Diarrhoea 4 (1.0) 0 0
Stomatitis 2 (0.5) 0 0
Neuropathy, motor 2 (0.5) 0 0
Neuropathy, sensory 2 (0.5) 0 0
Thromboembolism 1 (0.3) 2 (0.5) 0
Suddent death 0 0 1 (0.3)
Anaemia 4 (1.0) 1 (0.3) 0
Thromocytopenia 0 1 (0.3) 0
Neutropenia 12 (3.1) 35 (9.0) 0
Febrile neutropenia 15 (3.8) 9 (2.3) 0
Infections with neutropenia 5 (1.3) 4 (1.0) 0
Any event 65 (16.7) 49 (12.6) 1 (0.3)
CHAARTED1 LATITUDE2
AE, adverse event; ALT, alanine transaminase; AST, aspartate aminotransferase.
AE, %
Gra
Hypertension 2
Hypokalaemia 1
ALT increase
AST increase
Hyperglycaemia
Bone pain
Cardiac events
Anaemia
Back pain
Fatigue
Spinal cord
compression
Safety: CHAARTED and LATITUDE
1. Sween
AE Grade 3 Grade 4 Grade 5
Patients, n (%)
Allergic reaction 7 (1.8) 1 (0.3) 0
Fatigue 16 (4.1) 0 0
Diarrhoea 4 (1.0) 0 0
Stomatitis 2 (0.5) 0 0
Neuropathy, motor 2 (0.5) 0 0
Neuropathy, sensory 2 (0.5) 0 0
Thromboembolism 1 (0.3) 2 (0.5) 0
Suddent death 0 0 1 (0.3)
Anaemia 4 (1.0) 1 (0.3) 0
Thromocytopenia 0 1 (0.3) 0
Neutropenia 12 (3.1) 35 (9.0) 0
Febrile neutropenia 15 (3.8) 9 (2.3) 0
Infections with neutropenia 5 (1.3) 4 (1.0) 0
Any event 65 (16.7) 49 (12.6) 1 (0.3)
CHAARTED1 LA
AE, adverse vent; ALT, alanine transaminase; AST, aspartate aminotransferase.